- Home
- APLS vs XENE Comparison
APLS vs XENE Comparison
Compare APLS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- XENE
- Stock Information
- Founded
- APLS 2009
- XENE 1996
- Country
- APLS United States
- XENE Canada
- Employees
- APLS N/A
- XENE N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- XENE Health Care
- Exchange
- APLS Nasdaq
- XENE Nasdaq
- Market Cap
- APLS 2.3B
- XENE 2.5B
- IPO Year
- APLS 2017
- XENE 2014
- Fundamental
- Price
- APLS $17.30
- XENE $35.07
- Analyst Decision
- APLS Buy
- XENE Strong Buy
- Analyst Count
- APLS 19
- XENE 9
- Target Price
- APLS $39.06
- XENE $56.22
- AVG Volume (30 Days)
- APLS 2.7M
- XENE 853.6K
- Earning Date
- APLS 05-07-2025
- XENE 05-12-2025
- Dividend Yield
- APLS N/A
- XENE N/A
- EPS Growth
- APLS N/A
- XENE N/A
- EPS
- APLS N/A
- XENE N/A
- Revenue
- APLS $775,839,000.00
- XENE N/A
- Revenue This Year
- APLS $12.25
- XENE N/A
- Revenue Next Year
- APLS $21.08
- XENE $1,553.36
- P/E Ratio
- APLS N/A
- XENE N/A
- Revenue Growth
- APLS 48.04
- XENE N/A
- 52 Week Low
- APLS $16.65
- XENE $26.74
- 52 Week High
- APLS $43.99
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- APLS 34.14
- XENE 50.20
- Support Level
- APLS $16.65
- XENE $34.47
- Resistance Level
- APLS $20.75
- XENE $36.44
- Average True Range (ATR)
- APLS 1.09
- XENE 1.44
- MACD
- APLS 0.14
- XENE -0.19
- Stochastic Oscillator
- APLS 15.85
- XENE 28.63
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.